Treatment of Patients with Hypertension and Arthritis Pain: New Concepts

American Journal of Medicine

Volumn 122, Issue 5 SUPPL., 2009, Pages

  Weber, Michael A ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

Arthritis; Cyclooxygenase inhibiting nitric oxide donators; Hypertension; Naproxcinod; Nonsteroidal anti inflammatory drugs

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; NAPROXCINOD; NAPROXEN; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; ROFECOXIB; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIGESTIVE SYSTEM ULCER; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; HYPERTENSION; INFLAMMATION; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASCULARIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ARTHRITIS; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NITRIC OXIDE; NITRIC OXIDE DONORS; PAIN;

EID: 64849109591     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.03.004     Document Type: Article

References (29)

1. Mason R.P., Kubant R., Jacob R.F., Walter M.F., Boychuk B., and Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 48 (2006) 862-869
2. Panza J.A., Quyyumi A.A., Callahan T.S., and Epstein S.E. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 21 (1993) 1145-1151
3. Elliott T.G., Cockcroft J.R., Groop P.H., Viberti G.C., and Ritter J.M. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 85 (1993) 687-693
4. Calver A., Collier J., and Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90 (1992) 2548-2554
5. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., and Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993) 2510-2516
6. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27 (1996) 567-574
7. Campia U., Choucair W.K., Bryant M.B., Waclawiw M.A., Cardillo C., and Panza J.A. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol 40 (2002) 754-760
8. Perticone F., Ceravolo R., Pujia A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104 (2001) 191-196
9. Giles T.D. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 8 suppl 4 (2006) 2-16
10. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., and Taubert K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
11. Wallace J.L., and Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 15 (1994) 405-406
12. Muscara M.N., McKnight W., Lovren F., Triggle C.R., Cirino G., and Wallace J.L. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol 279 (2000) H528-H535
13. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M.B., and Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107 (1994) 173-179
14. Cicala C., Ianaro A., Fiorucci S., et al. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol 130 (2000) 1399-1405
15. Wallace J.L., and Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 17 (2003) 11-20
16. Naproxcinod. Data on file. NiCox, Sophia Antipolis, France, 2006.
17. Whittle B.J. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance [Thirteenth Gaddum Memorial Lecture]. Br J Pharmacol 110 (1993) 3-17
18. Wallace J.L. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med 19 (1996) 346-351
19. Rossoni G., Manfredi B., Del Soldato P., and Berti F. The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J Pharmacol Exp Ther 310 (2004) 555-562
20. Rossoni G., Manfredi B., De Gennaro Colonna V., et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol Res 53 (2006) 359-366
21. Davies N.M., Roseth A.G., Appleyard C.B., et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 11 (1997) 69-79
22. Silverstein F.E., Faich G., Goldstein J.L., et al., Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 284 (2000) 1247-1255
23. Fiorucci S., Santucci L., Wallace J.L., et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A 100 (2003) 10937-10941
24. Fiorucci S., de Lima Jr. O.M., Mencarelli A., et al. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123 (2002) 1598-1606
25. Fiorucci S., Di Lorenzo A., Renga B., Farneti S., Morelli A., and Cirino G. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-α-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther 311 (2004) 1264-1271
26. Presotto C., Bolla M.I., Olivieri R., Schnitzer T.J., and Wallace J.L. HCT 3012 reduces blood pressure in the spontaneously hypertensive rat model. Arthritis Rheum 54 suppl (2006) Presentation 231. S147.
27. Muscara M.N., McKnight W., Del Soldato P., and Wallace J.L. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 62 (1998) PL235-PL240
28. Lohmander L.S., McKeith D., Svensson O., et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64 (2005) 449-456
29. Schnitzer T.J., Kivitz A.J., Lipetz R.S., Sanders N., and Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum 53 (2005) 827-837